Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Malignancies|Breast Cancer - ER+, HER2 -|Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
Interventions: DRUG: AZD8835|DRUG: AZD8835|DRUG: AZD8835 in combination with fulvestrant|DRUG: AZD8835 in combination with fulvestrant
Sponsor: AstraZeneca